Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and equivalents	$ 121,103	$ 139,698
Inventories, net	15,312	14,478
As Restated [Member]
Current Assets:
Cash and equivalents	121,103	139,698
Marketable securities	3,312	3,310
Accounts receivable, net of allowance for doubtful accounts of $239 and $228, respectively	52,379	92,169
Inventories, net	15,312	14,478
Prepaid expenses and other current assets	7,149	2,745
Deferred tax asset	13,027	12,473
Total current assets	212,282	264,873
Property and equipment, net	2,004	2,548
Intangible assets, net	196,786	200,234
Goodwill	7,246	7,279
Deferred tax asset	29,676	23,276
Other assets	8,755	6,745
TOTAL ASSETS	456,749	504,955
Current Liabilities:
Accounts payable and other accrued obligations	83,592	93,811
Accrued compensation and related expenses	4,363	4,835
Deferred revenue	2,000	12,300
Deferred development costs	3,251	856
Accrued drug development costs	9,089	11,441
Total current liabilities	102,295	123,243
Deferred revenue and other credits-less current portion	3,680	2,937
Deferred development costs, less current portion	15,400	11,377
Deferred payment contingency		2,287
Other long-term obligations	6,130	1,430
Revolving line of credit	50,000	75,000
Total liabilities	177,505	216,274
Commitments and contingencies
Stockholders' Equity:
Preferred stock	0
Common stock, $0.001 par value; 175,000,000 shares authorized; 60,284,571 and 60,026,675 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	60	60
Additional paid-in capital	468,653	463,710
Accumulated other comprehensive gain	1,050	273
Accumulated deficit	(190,642)	(175,485)
Total stockholders' equity	279,244	288,681
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	456,749	504,955
Series B junior participating preferred stock [Member] | As Restated [Member]
Stockholders' Equity:
Preferred stock
Series E convertible voting preferred stock [Member] | As Restated [Member]
Stockholders' Equity:
Preferred stock	$ 123	$ 123